Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of clopidogrel low responders by a rapid CYP2C19 activity test.

Journal of atherosclerosis and thrombosis - 1 Jan 2012

Tazaki Junichi, Jinnai Toshikazu, Tada Tomohisa, Kato Yoshihiro, Makiyama Takeru, Ikeda Tomoyuki, Yamane Keiichiro, Naruse Yumiko, Takahashi Kanako, Watanabe Haruyo, Kimura Takeshi, Horiuchi Hisanori

Abstract excerpt

AIM: Clopidogrel, an essential drug for the prevention of stent thrombosis, is a prodrug activated by CYP enzyme family including CYP2C19. It is known that activity-defective polymorphisms of CYP2C19 (CYP2C19*2 and*3) are associated with reduced clopidogrel efficacy and poor prognosis. Recently, the (13)C-pantoprazole breath test is developed to evaluate the CYP2C19 activity. The aim of this study is to evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Breath Tests

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbon Radioisotopes

Share to Clopidogrel

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Proton Pump Inhibitors

Share to Ticlopidine

Source

Identifiers

PMID: 22166969
DOI: 10.5551/jat.10009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of clopidogrel low responders by a rapid CYP2C19 activity test.PMID 22166969Read ↗

[13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel.Semantic proximity Read ↗

Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.Semantic proximity Read ↗

CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.Semantic proximity Read ↗

Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.Semantic proximity Read ↗

Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.Semantic proximity Read ↗

Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?Semantic proximity Read ↗

Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients.Semantic proximity Read ↗

Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.Semantic proximity Read ↗

Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.Semantic proximity Read ↗

Utility of the 13 C-pantoprazole breath test as a CYP2C19 phenotyping probe for children.Semantic proximity Read ↗

Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.